Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704984 | 0.85 | GAA (0.40) | ALDH1A1MAPTLMNAKMT2AGAA | |
| SCHEMBL14436817 | 0.85 | GAA (0.40) | ALDH1A1MAPTLMNAKMT2AGAA | |
| SCHEMBL4757438 | 0.82 | DPP4 (0.41) | DPP4SLC6A9 | |
| SCHEMBL5662929 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAKMT2ADPP4 | |
| SCHEMBL5662706 | 0.81 | PDE7A (0.40) | MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL9984217 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAKMT2ADPP4 | |
| SCHEMBL14441574 | 0.79 | PDE7A (0.38) | ALDH1A1MAPTLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL4704511 | 0.78 | LMNA (0.59) | ALDH1A1MAPTLMNAKMT2AGAA | |
| SCHEMBL14437393 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL14436827 | 0.77 | PDE7A (0.38) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979318-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | claimed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | claimed |
| EP-1979318-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089683-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197530-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, HSD17B11, CYP11B1 | ALDH1A1 165/4885MAPT 3520/4885LMNA 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.